Intragel Therapeutics signs Urogen collaboration; up to $7M equity
URGN-linked Intragel Therapeutics and Urogen Pharma enter strategic collaboration and investment agreements, with Intragel securing up to $7M equity for a Phase 2 tumocure study.
URGN intragel Therapeutics and Urogen Pharma sign strategic collaboration and investment agreements to advance sustained-released investigational Oncology Therapies Intragel Therapeutics - intragel secures up to $7M equity investment from Urogen for phase 2 tumocure study - Urogen receives exclusive option for worldwide license to develop and commercialize tumocure